Press Room

Press Clipping / Mar 22, 2018

Five Minutes with Marco Gil - DCAT WEEK’18

TKS, TeckoScienze Publisher, March 22, 2018

Marco Gil picture ɫAV Senior VP Sales and Marketing

Marco Gil

Senior VP - Sales & Marketing
Marco Gil has a degree in Chemical Engineering and a Ph.D. in Chemistry from the Technical University of Lisbon.

In 2007 he joined ɫAV as an Associate Engineer in the R&D Particle Design area. In May 2011 he was appointed as a Director of R&D Process Chemistry. He has held several management responsibilities, including Site General Manager of the ɫAV site in New Jersey, US. From 2017 to 2022, Marco held leadership positions in Sales.

Since May 2022 he is the Senior Vice-President of Sales & Marketing at ɫAV.

PH: How is business right now?

Gil: Business is going well. The CDMO industry is quite busy, not just ɫAV. It comes naturally from the good environment that investors found in the biotech sector overall, so there are many programmes ongoing in development. Business is well funded, there is a lot of activity and CDMOs benefit from that. Also, large pharma continues to divest manufacturing assets. The trends of recent years remain and I think they will continue for the next months. The off-patents business is growing too. There is a lot of interest in niche, specialised APIs with specific properties from a physical standpoint.

PH: What specialised technologies are you investing in?

Gil: Spray drying is one of our core technologies,...

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024